Lung Cancer Biomarkers Market
Lung Cancer Biomarkers Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Lung Cancer Biomarkers Market Size and Growth
The global Lung Cancer Biomarkers market is expected to reach a value of $7.85 billion by 2026, with a CAGR of 13.5%. Key market drivers include increasing prevalence of lung cancer, advancements in biomarker technologies, and growing demand for personalized medicine. Key players in the market include Roche, Thermo Fisher Scientific, and Illumina.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Bio-Rad Laboratories
◍ Roche Diagnostics
◍ Qiagen
◍ Illumina
◍ GE Healthcare
◍ Agilent Technologies
◍ Biomerieux SA
◍ Merck
◍ Abbott Laboratories
◍ Becton, Dickinson and Company
◍ Danaher Corporation
◍ Myriad Genetics
◍ Sysmex Corporation
◍ Hologic
The lung cancer biomarkers market is highly competitive with key players such as Bio-Rad Laboratories, Roche Diagnostics, Qiagen, Illumina, GE Healthcare, Agilent Technologies, Biomerieux SA, Merck, Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, Myriad Genetics, Sysmex Corporation, and Hologic. These companies develop and market biomarker testing kits, diagnostic tools, and personalized medicine solutions to support early detection and treatment of lung cancer, thus aiding in the growth of the market.
- Bio-Rad Laboratories: $2.43 billion in 2020
- Roche Diagnostics: $52.1 billion in 2020
- Merck: $46.3 billion in 2020
Request Sample Report
Market Segmentation
By Application
Diagnostics
Research
Others
Request Sample Report
By Product
Protein Biomarker
Genetic Biomarker
◍
◍
◍
◍
◍
Market Growth
Request Sample Report
$ X Billion USD
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients